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Abstract
Background: The aim of the study was to investigate the effect of dietary supplementation with zinc and
polyphenol compounds, i.e. resveratrol and genistein, on the effectiveness of chemically induced mammary cancer
and the changes in the content of selected elements (Zn, Cu, Mg, Fe, Ca) in tumors as compared with normal
tissue of the mammary gland.
Methods: Female Sprague-Dawley rats were divided into study groups which, apart from the standard diet and
DMBA (7,12-dimethyl-1,2- benz[a]anthracene), were treated with zinc ions (Zn) or zinc ions + resveratrol (Zn +
resveratrol) or zinc ions + genistein (Zn + genistein) via gavage for a period from 40 days until 20 weeks of age.
The ICP-OES (inductively coupled plasma optical emission spectrometry) technique was used to analyze the
following elements: magnesium, iron, zinc and calcium. Copper content in samples was estimated in an atomic
absorption spectrophotometer.
Results: Regardless of the diet (standard; Zn; Zn + resveratrol; Zn + genistein), DMBA-induced breast
carcinogenesis was not inhibited. On the contrary, in the Zn + resveratrol supplemented group, tumorigenesis
developed at a considerably faster rate. On the basis of quantitative analysis of selected elements we found -
irrespectively of the diet applied - great accumulation of copper and iron, which are strongly prooxidative, with a
simultaneous considerable decrease of the magnesium content in DMBA-induced mammary tumors. The
combination of zinc supplementation with resveratrol resulted in particularly large differences in the amount of the
investigated elements in tumors as compared with their content in normal tissue.
Conclusions: Diet supplementation with zinc and polyphenol compounds, i.e. resveratrol and genistein had no
effect on the decreased copper level in tumor tissue and inhibited mammary carcinogenesis in the rat.
Irrespectively of the applied diet, the development of the neoplastic process in rats resulted in changes of the iron
and magnesium content in the cancerous tissue in comparison with the healthy mammary tissue. The application
of combined diet supplementation with zinc ions and resveratrol considerably promoted the rate of carcinogenesis
and increased the number of DMBA-induced mammary tumors.
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Background
The disturbances in minerals homeostasis may induce
biochemical changes characteristic of many diseases,
including neoplastic diseases [1]. For instance, dietary
insufficiencies in selenium, zinc and magnesium ele-
ments, and excess intake of copper and iron may
increase the cancer risk [2-5]. It was uncovered in
many investigations that in mammary malignant tumors
an increased copper content is found in comparison
with normal tissue and that ceruloplasmin level signifi-
cantly increases in neoplastic diseases [6-8]. High copper
concentration results in increased oxidative stress in the
cells, and thus to modification of many cell structures
[6]. Copper has high affinity to DNA, it has the stron-
gest ability to bind to DNA of all other divalent cations
* Correspondence: dorota.skrajnowska@wum.edu.pl
Department of Bromatology, Faculty of Pharmacy, Medical University of
Warsaw, Banacha 1, Warsaw 02-097, Poland
Bobrowska-Korczak et al. Journal of Biomedical Science 2012, 19:43
http://www.jbiomedsci.com/content/19/1/43
© 2012 Bobrowska-Korczak et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.and it can impair DNA structure via oxidation. These
impairments together with inadequate rate of the biolo-
gical system’s ability to repair the resulting damage and
with simultaneous permanent exposure to the reactive
oxygen species may result in the onset of the process of
carcinogenesis. In addition, copper plays a considerable
role in the process of angiogenesis of malignant cells, as
it is indispensable for activation of endothelial cells.
Many compounds characterized by various mechanisms
of inhibiting the development of blood vessels have
already been introduced into clinical trials. Copper has
become one of therapeutic targets in antiangiogenic
anticancer treatment.
In the last few years many experiments have been per-
formed that confirmed the usefulness and effectiveness of
the action of copper reducing and chelating agents in anti-
angiogenic therapy [7,9]. Specialists in clinical research are
also interested in the possibility of using zinc, which is a
natural copper antagonist, in adjunctive therapy to reduce
the copper level [7]. On the other hand, the results of
investigations into the effect of polyphenol compounds
applied in different doses on the formation and prolifera-
tion of malignant cells, using various mechanisms includ-
ing the use of antioxidants to remove free radicals and
copper ions chelation, as well as their effect on the cell
cycle are promising enough to justify the usefulness of
their application in anti-carcinogenic therapy [10-12].
The aim of investigations
The aim of the study was to investigate the effect of
dietary supplementation with zinc and polyphenol com-
pounds, i.e. resveratrol and genistein, on the effective-
ness of chemically induced mammary cancer and the
changes in the content of selected elements (Zn, Cu,
Mg, Fe) in tumors as compared with normal tissue of
the mammary gland.
Methods
Animals
Fifty-six 30-days-old Spraque-Dawley female rats of 100 ±
20 g body weight, were subjected to a 10-day adaptation
period. The animals were housed in stainless steel cages
under controlled conditions (22 ± 1°C, a 12 h light - dark
cycle), with a free access to a standard laboratory diet
(Labofeed H, Poland) and drinking water. The rats were
obtained from the Laboratory of Experimental Animals,
Department of General and Experimental Pathology, Med-
ical University of Warsaw (Warsaw, Poland). The animal
experiments were approved by the Ethics Committee,
Medical University of Warsaw.
Experimental design
The experiment was conducted for 14 weeks (from 40
days until 20 weeks of age). After the adaptation
period, the animals were divided into two experimental
groups. In group 1 (DMBA+, study group n = 33), the
rats were treated with a dose of 80 mg/body weight of
DMBA (7,12-dimethyl-1,2- benz[a]anthracene; Sigma-
Aldrich, St. Louis, MO, USA) given in rapeseed oil at
50 and 80 days of age to induce breast cancer (adeno-
carcinoma), and in group 2 (DMBA-, control group n
= 23), the rats were accommodated under the same
conditions as those in Group 1; fed the same diet, but
without DMBA treatment. Tumors were histopatholo-
gically evaluated to confirm their malignancy and to
prove that they were adenocarcinomas (II and III
degree). Spontaneous cancers were not found in the
non-DMBA groups.
Animals from both groups were also fed diets different
in bioelements. The diets were supplemented with:
- Zn - the exposed group received a daily via gavage,
0.4 mL of Zn (6.9 mg/mL; i.e. 231 mg Zn/kg diet) (as
ZnSO4·7 H 2O in aqueous suspension)
- Zn + resveratrol - the group received a daily via
gavage, 0.4 mL of Zn (6.9 mg/mL) and resveratrol (0.1
mg/mL; i.e. 0.2 mg/kg bw) in aqueous suspension
- Zn + genistein - the group received a daily via
gavage, 0.4 mL of Zn (6.9 mg/mL) and genistein (0.1
mg/mL; i.e. 0.2 mg/kg.bw) in aqueous suspension.
The animals without supplementation recived daily via
gavage 0.4 mL of water.
The dose of Zn was established based on the value
used in the Labofeed H diet (standard diet) (77 mg Zn/
kg diet - Table 1). The polyphenols dose level was
selected based on human average daily consumption
(extrapolating on the rats’ body weight).
Samples and measurements
The animals were sacrificed by decapitation at 20 weeks
of age, and tumor as well as normal tissues of the mam-
mary gland were collected. The samples were stored at
a temperature of -70°C until the test time. The mineral
content was determined after wet microwave mineraliza-
tion of the samples. Approximately 500-800 mg samples
of tumors and normal mammary tissues or fodder were
placed in a teflon vessel and with added 3.5 mL of 65%
nitric acid (Suprapur
®, Merck, Germany). The vessels
were placed in a microwave system (MULTIWAVE,
Anton Paar, Perkin Elmer) and their content was
mineralized. The ICP-OES technique (Optima 3100XL,
Perkin Elmer) was used to analyze the following ele-
ments: magnesium (Mg), iron (Fe), zinc (Zn) and cal-
cium (Ca). Copper (Cu) content in samples was
evaluated using an atomic absorption spectrophot-
ometer (PU 9100) with air-acetylene flame. The analy-
sis of fodder was performed in order to check if the
Zn content was in agreement with the amount
declared by the producer. The obtained results were
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declared by the producer (data not shown).
Validation
The intralaboratory quality control of determination was
done using the following certified Reference Materials
(percent of recovery for a given element and relative
standard deviation (RSD)):
- NCS ZC 71001 Beef Liver (recoveries: Cu - 118%;
Fe - 109%; Ca - 115%; Zn - 105%; Mg - 96%; RSDs -
C u-7 , 2 % ;F e-4 , 9 % ;C a-5 . 0 % ;Z n-3 , 5 % ;M g-
4,6%)
- NIST 1577b Bovine liver (recoveries Cu - 116%; Fe -
103%; Ca - 103%; Zn - 107%; Mg - 105%; RSDs - Cu -
13%; Fe - 1,8%; Ca - 3%; Zn - 1,8%; Mg - 1%)
Limits of detection (LOD) for: Zn - 0.03 mg/L; Ca -
1.47 mg/L; Fe - 0.17 mg/L; Mg - 0.04 mg/L and Cu -
0.13 mg/L.
Statistics
Data are given as means ± SD (for iron, zinc, copper
and magnesium). The results were compared to those
in the control animals, in order to elucidate the possible
effect of Zn or phenolic compounds supply on tumori-
genesis and the mineral composition of tumor. The data
were analyzed using Student’s t-test; differences at p ≤
0.05 were considered statistically significant. The non-
parametric t test (Mann - Whitney test) was applied
for the parameter without normal distribution (cal-
cium concentration).
Results
Carcinogenesis
It is a relevant issue to assess the severity of carcinogen-
esis expressed by tumor weight and number in particu-
lar rat groups as well as the onset time of initial tumors.
Irrespectively of the diet applied, the effectiveness of
DMBA-induced carcinogenesis was 100% (Table 2).
Only in the group of rats supplemented with Zn + gen-
istein, one animal developed no tumors. There were
both single and multiple tumors - on average up to 6
tumors per rat, the group supplemented with Zn +
resveratrol was characterized by a maximal number of
10 tumors per rat. In this group (receiving Zn + resvera-
t r o l )t h ef i r s tt u m o r sa p p e a r e da t1 3w e e k so fa g e ,i . e .
two weeks earlier than in the groups receiving Zn or Zn
+ genistein or only the standard diet.
Mineral content in control tissuse (DMBA-)
An appraisal was done of the effect of dietary supple-
mentation on the content of elements in normal tissues
as compared with the content of the same elements in
normal mammary gland tissue in rats that were fed a
standard diet only.
The applied Zn dose (exceeding threefold the amount
of that element in the fodder) effectively reduced the
copper level in normal tissue of the mammary gland in
comparison with normal tissue in rats that were fed an
unsupplemented standard diet. Similarly the copper
content was reduced by over 40% for the groups that
received Zn and Zn + resveratrol and by over 33% for
the groups supplemented with Zn + genistein (Table 3).
The Ca content in normal tissue was significantly
elevated in the group supplemented with Zn + genis-
tein in comparison with normal tissue in rats that
were fed an unsupplemented standard diet (Table 4).
No differences were found with respect to the remaining
elements (Table 3).
The mean values and confidence intervals were calcu-
lated for data transformed in logarithms, and then
retransformed after calculations. P values were calcu-
lated using non-parametric test (Mann-Whitney test); n
- number of samples.
Zinc and calcium content in tumors
The applied excessive zinc supply did not affect the
amount of that element in the malignant tissue, irre-
spectively of whether zinc was supplied alone or in com-
bination with polyphenols in doses corresponding to
Table 1 Declared dietary composition of Labofeed H (per
kg of diet)
Protein (g) 210.0
Fat (g) 39.2
Fiber (g) 43.2
Starch (g) 300.0
Ash (g) 55.0
Vitamin A IU 15000 Lysine g 14.5
Vitamin D3 IU 1000 Methionine g 4.1
Vitamin E mg 90.0 Tryptophan g 3.0
Vitamin K3 mg 3.0 Threonine g 7.4
Vitamin B1 mg 21.0 Isoleucine g 17.5
Vitamin B2 mg 16.0 Valine g 11.0
Vitamin B6 mg 17.0 Histidine g 6.0
Vitamin B12 μg 80.0 Arginine g 13.0
Pantothenate mg 30.0 Phenylalanine g 10.0
Folic acid mg 5.0 Tyrosine g 7.8
Nicotinic acid mg 133.0 Choline mg 2750.0
Biotin mg 0.4
Calcium g 10.0 Iron mg 250.0
Phosphorus total g 8.17 Manganese mg 100.0
Phosphorus saturated g 4.5 Zinc mg 76.9
Magnesium g 3.0 Copper mg 21.3
Potassium g 9.4 Cobalt mg 2.0
Sodium g 2.2 Iodine mg 1.0
Chlorine g 2.5 Selenium mg 0.5
Sulfur g 1.9
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weight (Table 3).
The Ca content in tumors was significantly elevated in
the groups supplemented with Zn + resveratrol and
Zn + genistein. Generally, considerable differences
occurred in Ca content, irrespectively of the group or
diet (Table 4).
Copper, iron and magnesium content in tumors
The applied doses of zinc, resveratrol and genistein were
found to significantly change the copper, iron and mag-
nesium content in malignant mammary gland tumors as
compared with normal tissue (Table 3).
The copper content increased by as much as 135% in
the group supplemented with Zn + resveratrol, by 93%
in the group supplemented with Zn, and by 64%i nt h e
group supplemented with Zn + genistein. No significant
differences were found in the group of rats that were
fed a standard diet only (Table 3).
The iron content in tumors also significantly
increased: by more than 200% in groups of rats fed a
standard diet and those supplemented with Zn + resver-
atrol; by 100% in the groups supplemented with Zn +
genistein, and by 55% in tumors of the rats that received
a diet supplemented with Zn (Table 3).
The magnesium content in malignant tissue as com-
pared with normal tissue was significantly reduced by
over 30% in all groups (Table 3).
Discussion
In our in vivo investigations the applied dose of zinc was
three times higher than the amount of zinc normally
found in the fodder (also in combination with polyphe-
nols) and this effectively reduced the copper content in
normal tissue of mammary gland in the rats of the con-
trol group as compared with the rats fed a standard diet
only. Therefore it can be supposed that the applied dose
of zinc and polyphenols had a positive effect as it
reduced the amount of copper in the body without
causing any toxic effect such as loss of appetite (unwill-
ingness to eat) or loss of body weight.
However, DMBA-induced chemical carcinogenesis
changed the situation completely. Irrespectively of the
applied diet, no decrease of copper content was
observed in already existing tumors. On the contrary,
the supplementation with zinc or zinc + polyphenols
Table 2 Cancer induction in 7,12-dimethyl-1,2- benz[a]anthracene treated groups in relation to the diet applied
diet Tumors in
group
Number of tumors in one
rat
Maximum tumor weight
(g)
First week at
onset
1. standard diet 9/9 (100%) 1 - 5 12 15
2. zinc 6.9 mg/mL
(231 mg Zn/kg diet)
9/9 (100%) 1 - 5 20 15
3. zinc 6.9 mg/mL
(231 mg Zn/kg diet)
and resveratrol 0.1 mg/mL (0.2 mg/kg
bw)
10/10 (100%) 2 - 10 30 13
4. zinc (6.9 mg/mL)
(231 mg Zn/kg diet)
and genistein 0.1 mg/mL (0.2 mg/kg bw)
10/11 (91%) 1 - 6 15 15
The date refer to tumors evaluated at 20 weeks of the animals’ age (decapitation time)
Table 3 Altered mineral content in cancerous tissues (DMBA+) vs mineral content in normal tissues (DMBA-) (μg/g wet
weight)
diets
elements DMBA Standard Zn Zn + resveratrol Zn + genistein
Mean ± SD (n) RSD% Mean ± SD (n) RSD% Mean ± SD (n) RSD% Mean ± SD (n) RSD%
Zn (μg/g) - 17.6 ± 1.7 (5) 9.6 18.2 ± 1,3 (6) 7.1 18.5 ± 1.3 (6) 7.3 17.2 ± 2.3 (6) 13
+ 17.6 ± 0.9 (7) 5.1 17.3 ± 1.3 (8) 7.5 19.2 ± 1.2 (8) 6.1 17.0 ± 1.1 (10) 6.6
Cu (μg/g) - 2.57 ± 0,79 (5) 30 1.36 ± 0.22 (6)** 15 1.47 ± 0.19 (6)** 12 1.74 ± 0.45 (6) 26
+ 2.92 ± 0.85 (7) 29 2.63 ± 0.52 (8) * 19 3.45 ± 0.82 (8) * 23 2.87 ± 0.79 (8) * 27
Fe (μg/g) - 17.7 ± 3.1 (5) 17 18.6 ± 2.2 (6) 12 17.1 ± 2.4 (6) 13 16.3 ± 2.1 (5) 12
+ 50.7 ± 22.6 (7) * 44 28.9 ± 6.3 (8) * 21 51.4 ± 19 (8) * 36 33.4 ± 9.6 (10) * 28
Mg (μg/g) - 224.4 ± 33.8 (5) 15 263.5 ± 7.66 (6) 2.9 228 ± 14.7 (6) 6.4 236.8 ± 18.7 (6) 7.8
+ 153.6 ± 10,5 (7) * 6.8 166.5 ± 11.3 (8) * 6.7 146.4 ± 12.1 (8) * 8 160.8 ± 9.3 (10) * 5.8
*differences (p ≤ 0.05) between concentrations of metals in DMBA (+) and DMBA (-) groups of each type of diet
**differences (p ≤ 0.05) between concentrations of metals in each type of diet (DMBA-) relative to standard diet (DMBA-)
SD - standard deviation; RSD - relative standard deviation (%); n- number of samples
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tumors. Thus it seems that a key role in this effective
accumulation of copper was played by a combination of
Zn and DMBA, and to some extent by polyphenols.
Copper plays a significant role in the process of neoplas-
tic angiogenesis. Malignant tumors can develop relatively
e a s i l yu pt ot h es i z eo f1 - 2m m
3. Their further growth
requires the formation within the tumor of a network of
blood vessels that ensure better cell nourishment, and also
allow their expansion in the form of metastases [7]. The
process of angiogenesis begins as a result of metabolic oxi-
dative stress in tumor cells. The first stage of this process
always involves the activation of endothelial cells. The
copper ions have a stimulating effect on the proliferation
process, through their activating role with respect to var-
ious growth factors such as VEGF (vascular endothelial
growth factor), TNF (tumor necrosis factor), EGF (epider-
mal growth factor) or IL-1 (interleukin 1). The factors that
have been activated bind with receptors in endothelial
cells. As a result, the cell passes from phase G0 to phase
G1 and the cell proliferation process is activated. Besides,
the presence of copper is required for some proteins to
obtain antigenic properties, e.g. for ceruloplasmin, angio-
genin or glycyl-L-histydyl-L-lysine tripeptide [7]. The
investigations of Brem and Wotoczko-Obadio [13] showed
that after decreasing copper concentration by using peni-
cillamin and a special diet poor in copper the proliferating
cell can enter phase G0 again, or apoptosis can occur, as a
result of which the angiogenic activity of VEGF, TNF, EGF
or IL-1 is inhibited [13].
Therefore, because of a very important role of copper
in tumor angiogenesis, it seems necessary to search for
compounds that would have a chelating effect or that
would reduce its amount in the bloodstream. Zinc is a
natural copper antagonist. Zinc-induced metallothio-
neins in intestinal lumen bind to copper thus inhibiting
its absorption into the bloodstream. Reduction of copper
concentration to 20% of its physiological level is consid-
ered to be a favorable therapeutic response (various dis-
eases of fibrosis and/or inflammation) [14-16]. It
seems that this low copper concentration is enough to
activate Cu-dependent enzymes and at the same time to
inhibit tumor growth. In order to decrease the copper
content more rapidly, zinc ions are used as adjunct
medication together with o t h e rc o p p e rc h e l a t e s( d -
penicillamine, thiomolybdate or biogenic methano-
bactin) [12,16,17]. It is known that long-term increased
zinc supplementation has no toxic results, which can be
seen in the treatment of Wilson’sd i s e a s e[ 1 7 , 1 8 ] .O n e
drawback of the antiangiogenic zinc treatment is that it
is only effective when supplied over long periods of
time. In order to reduce the Cu level to 20% of its phy-
siological value zinc must be supplied in a dose three
times as high as the average daily demand for zinc, i.e.
in pharmacological doses of 40-50 mg/day, and for a
period of up to six months [18].
Zinc is a chemical element that takes part in prolifera-
tion and reproduction of cells, in transcription and
repair of DNA damage as well as in storage and libera-
tion of hormones. It also plays an immunological role
and provides an important antioxidant defense against
free radicals (by way of copper and zinc superoxide dis-
mutation, antagonistic activity with respect to transition
metals, protection against the oxidation of sulfhydryl
groups of enzymes as exemplified by δ-aminolevulin
desaturase, induction of metallothionein expression as
well as regulation of apoptosis). It can be said that intra-
cellular zinc concentration is decisive for the future of
the cell, its proliferation, differentiation, and cell death
by necrosis. Many investigations confirmed the phenom-
enon of zinc accumulation in human mammary gland
tumors as well as in chemically induced tumors in ani-
mals by using N-methyl-N-nitrosourea (MNU) [19,20].
Zinc is essential for cell proliferation and differentia-
tion, especially for the regulation of DNA synthesis
and mitosis (as it is generally known that neoplastic
cells undergo uncontrolled proliferation).
However, in our investigations in which the rats with
DMBA-induced tumors were supplemented with zinc
every day for 100 days, no differences in zinc content
were found in comparison with normal tissue, irrespec-
tively of the diet applied. Even the comparison of con-
trol groups supplemented with zinc with control groups
fed a standard diet showed no differences in zinc con-
tent. It seems that also in this case the neoplastic tissue
did not accumulate more zinc (in spite of increased
Table 4 Altered calcium content in cancerous tissues
(DMBA+) vs calcium content in normal tissues (DMBA-)
(μg/g wet weight)
Diet DMBA(-)
Mean
(confidence
interval)
(n)
DMBA(+)
Mean
(confidence
interval)
(n)
p
Standard 234.8
(73.0 - 754.8)
(5)
404.4
(178.0 - 916.7)
(7)
<
0.343
Zn 216.4
(54.8 - 854.2)
(6)
97.8
(82.4 - 115.9)
(8)
<
0.949
Zn +
resveratrol
83.6
(58.5 - 119.5)
(6)
510.1*
(195.4 - 1334.7)
(8)
<
0.001
Zn + genistein 64.7**
(60.9 - 68.8)
(5)
219.7*
(97.9 - 493.6)
(10)
<
0.001
*differences between concentrations of calcium in DMBA (+) and DMBA (-)
groups of each type of diet
**differences between concentrations of calcium in each type of diet (DMBA-)
relative to standard diet (DMBA-)
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was shown in many studies that zinc insufficiency in the
body may lead to the development of different forms of
cancer, whereas zinc supplementation was proven to
inhibit cancer development [21,22]. So it might seem
that zinc supplementation applied in this study should,
at least by competing with copper and iron, effectively
weaken the process of cell proliferation. However, this
was not the case and so it can be supposed that cancer
cells have a specific strong ability to accumulate first of
all iron, but also copper, i.e. the elements that are indis-
pensable for triggering oxidative stress.
Iron not only facilitates the appearance of oxidative
stress, but also activates proinflammatory cytokines and
in the case of their excess leads to intracellular hypoxia
[5,23]. From epidemiological studies it results that the
risk of cancer is considerably increased in patients with
a large iron supply in comparison with those with nor-
mal or below normal content of this element [23]. It
was shown that breast cancer cells have 5-10-fold more
receptors for transferrins (TfR1) than normal cells of
the mammary gland, probably because they receive a
higher amount of iron. Meanwhile, another type of
transferrin receptors known as TfR2 was also found.
These receptors are present in many malignant cells and
may effectively contribute to the iron’s increased ability
of absorption [23]. The increased iron supply in the diet
increases the frequency of occurrence of carcinogen-
induced mammary cancer in rats and estrogen-induced
kidney cancer in hamsters [23]. Thus it is very probable
that by affecting iron metabolism and disturbing the
process of its accumulation in malignant tissues [23] it
m a yb ep o s s i b l et op r e v e n tan u m b e ro fd i f f e r e n tc a n -
cers. Some researchers hold that the lowering of iron
content may be a way to treat cancer, because in this
way the proliferation of tumors is limited (investiga-
tions performed on rats). In the investigations per-
formed both in vitro and in vivo it was shown that
deferoxamine, an iron-chelating agent that decreases its
bioavailability is effective in tumor cells treatment [23].
The results obtained by us concerning the increased
iron concentration in tumors are in agreement with the
results of other authors [19,24].
The present investigation showed that, irrespectively
of the type of supplementation applied, there was a con-
siderable increase of iron content in tumors in compari-
son with normal tissue, also for the standard group.
This may mean that supplementation with zinc and
polyphenols had no effect on the process of iron absorp-
tion by malignant tissues.
Similarly, there was no stimulating effect of the diet
applied on the magnesium content in malignant tissue.
In this case it seems that the carcinogen while causing
mutation and tumor formation, very strongly controls
the demand of those tissues for the given element. Irre-
spectively of the applied diet there was a decrease of
magnesium in malignant tissue in comparison with its
content in normal tissue of healthy rats that received an
analogical diet (i.e. the same diet in the control group
(DMBA-) and the examined group (DMBA+). This
effect is most pronounced in the groups supplemen-
ted with Zn and Zn + resveratrol.T h er e d u c e dmag-
nesium content was also found in patients with nasal
polyp, papilloma or laryngeal carcinoma [25]. The effect
of magnesium on the development of neoplasm may be
due to oxidative stress, DNA oxidation and the resulting
mutagenesis, as well as by affecting the DNA repair
mechanisms that are critical for the maintenance of gen-
ome stability [2].
In the present investigation resveratrol and genistein
were used as they are both strong antioxidants and che-
mopreventive compounds [10,11]. The hydroxyl groups
of polyphenols react with free radicals and form more
stable fenoxyl complexes. Besides, polyphenols while
causing complexation of Cu (II) and Fe (II) ions, may
inhibit the activity of some enzymes, e.g. of xanthine
oxidase and processes increasing the free radicals forma-
tion [26,27]. The chemopreventive activity of polyphe-
nols is multifactorial - ranging from inhibition of
cytochrome P-450 isoenzymes, induction of phase II
enzymes (UDP-glucuronyltransferase and NADPH oxy-
doreductase (28), inhibition of NFBI and AP-1 (activa-
tor protein 1) as well as of DNA topoisomerases I and
II and helicases, inhibition of angiogenesis, inhibition of
cyclooxygenase 1/2 enzymes, inducing NO synthesis and
increasing the p-53 protein expression), and finally to
exhibiting similar characteristics to steroid sex hor-
mones [12,28-30]. However, in investigations with the
use of various cell lines and animal models resveratrol
revealed opposing activities: estrogenic activity or anties-
trogenic activity [29]. In the estrogen-dependent cell
line of mammary cancer, in the case of estrogen defi-
ciency resveratrol behaved like a competitive estrogen
receptor agonist and stimulated the cell proliferation
[29,31], whereas in the presence of estrogen it acted as
an estrogen detector antagonist.
Similarly, genistein exhibits antiproliferative activity
with respect to human cells of breast cancer MCF-7
when applied in large pharmacological doses (> 10 μM),
and estrogenic activity when applied in small physiologi-
cal doses (0.1-1 μM) which however is considerably
weaker than that of natural estrogen [32,33]. In the
majority of investigations performed on animals genis-
tein was found to inhibit proliferation of mammary
tumors as well as of other forms of cancer [34].
One of the criteria showing that the animals are prone
to tumor induction is the moment when malignant cal-
luses are felt by palpation. In the case of our
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as t a n d a r dd i e tt h ef i r s tt u m o r sa p p e a r e da tt h es a m e
time (15th week) as in the groups that were supplemen-
t e dw i t hZ na n d / o rZ n+g e n i s t e i n .I nt h eg r o u po fr a t s
that received Zn + resveratrol the first tumors appeared
two weeks earlier than in the remaining groups (which
corresponds to a period of about 10-12 months in
humans) [35]. What is the reason of the difference
between the rate of tumorigenesis in the rats that were
fed a standard diet and those supplemented with Zn or
Zn + genistein, and an increased rate of tumor forma-
tion in the group of rats whose diet was supplemented
with Zn ions + resveratrol? In the studies of Win et al.
[36] on the effect of genistein and resveratrol on induc-
tion of plasmid DNA impairm e n t sb yr e a c t i v eo x y g e n
species (ROS) that formed in the medium H2O2/Cu(II)
and hydroquinone/Cu (II) it was shown that the activity
of these two polyphenols proceeds via different mechan-
isms. The presence of genistein in micromolar concen-
trations considerably inhibits DNA damage, however
not by affecting the Cu (II)/Cu (I) redox cycle or in
reaction with H2O2, but by working as an effective
agent that has the capacity to sweep away the reactive
oxygen species (ROS) that have formed. Contrary to
that, resveratrol present in similar concentrations (25
μM-200 μM) increases DNA breakage induced by
H2O2/Cu (II). Many researchers showed that it is resver-
atrol (and not genistein) that increases DNA damage in
the presence of Cu (II) ions. Neoplastic cells accumulate
great amounts of copper, including that bound in the
nucleus. Thus the formed complex resveratrol/Cu (II)
after binding to DNA may induce DNA breakage [36].
On the other hand,m a n yin vivo investigations con-
firmed that resveratrol supplemented in the diet may
reduce the occurrence and multiplicity of the chemically
induced mammary tumors, first of all by affecting COX
2, expression of metalloproteinases, and the nuclear fac-
tor B [37]. As a result the maturation of the mammary
gland is enhanced, which in turn leads to reduction of
cell proliferation and an increase of apoptosis in the
epithelium of mammary cells [37,38]. However, there
are also reports stating that short-term resveratrol sup-
plementation (depending on the dose) before pubes-
cence may result in endocrine disturbances and cause
irregular cycles with prolonged oestrus phase, which in
turn increases the multiplicity of mammary tumors in
rats [39]. Estrogens are known as important natural
mitogenic factors in human breast, which is connected
with an increased breast cancer risk. Resveratrol exhibits
anticarcinogenic activity on animal models [39] in the
case of skin cancer, when administered to adult animals.
It is worth noting that during the perinatal period the
organism is very sensitive and so the high level of expo-
sure to estrogens during pregnancy increases the risk of
mammary cancer in female offsprings [39]. However,
available data as concerns the interaction between mam-
mary cancer and estrogen level are still inconsistent.
The timing and level of exposure to estrogenic chemi-
cals are apparently important. There are reports claim-
ing that genistein administered to rats in the perinatal,
neonatal and pre-pubescence periods also induces irre-
gular oestrus cycles related to prolongation of the oes-
trus phase [39,40] and thus may accelerate the
development of mammary carcinoma. In another paper
[41] it was shown that phytoestrogens, including genis-
tein, when supplied during prepubescence reduce the
risk of mammary cancer development in the future.
As concerns resveratrol, there are few investigations
concerning this period. In adult rats resveratrol when
administered by a stomach tube or with the diet, signifi-
cantly inhibited mammary oncogenesis induced by
MNU or DMBA [42,43]. On the other hand, in the
paper of Sato et al. [39] resveratrol in a dose of 100 mg/
kg body weight accelerated the appearance of MNU-
induced mammary carcinomas, but no such activity was
observed when resveratrol was given in a dose of 10
mg/kg body weight.
Cancer incidence and multiplicity were significantly
higher in the high-dose group, whereas latency was
unchanged. As the majority (80%) of MNU-induced
mammary carcinomas are hormone-dependent resvera-
trol appears to increase the ER - and/or PgR-positive
cells presumed to be the progenitors of hormone-depen-
dent carcinomas resulting in a higher mammary carci-
noma yield [44,45].
In our investigations the lack of anticarcinogenic
activity of dietary supplementation with zinc ions and
polyphenols, or even acceleration of mammary oncogen-
esis in animals on the zinc + resveratrol supplemented
diet, may be related to sexual immaturity of the rats.
Conclusions
Summing up, it should be emphasized that the increased
supply of zinc alone or in combination with either
resveratrol or genistein resulted in a decrease of copper
content in normal tissue of the mammary gland,
whereas in the case of malignant tissue an opposite
effect was observed. On the basis of quantitative analysis
of selected elements we found - irrespectively of the diet
applied - great accumulation of copper and iron, which
are strongly prooxidative, with a simultaneous consider-
able decrease of the magnesium content in DMBA-
induced mammary tumors. The combination of zinc
supplementation with resveratrol resulted in particularly
large differences in the amount of the investigated ele-
ments in tumors as compared with their content in nor-
mal tissue. In addition, the supplementation with zinc +
resveratrol significantly increased the rate of appearance
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Page 7 of 9of the first tumors that could be felt by palpation as well
as their multiplicity, which is indicative of accelerated
oncogenesis. Perhaps a given phytoestrogen can have
opposing effects on mammary cancer risk, depending on
t h et i m eo fe x p o s u r e .T h ee x a c tm e c h a n i s mi sn o t
known, especially as each of the examined compounds
is rather considered to be an ally in the fight against
cancer. However, the presented results make us wonder
if the diet supplementation with several antioxidants at
t h es a m et i m ei sl i k e l yt oa f f o r dt h ee x p e c t e dr e s u l to f
inhibiting the risk of carcinogenesis, especially in chil-
dren and young people before pubescence.
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